GlassScriptPhysician profile
Jennifer M Duke
NPI 1932159266
$6,263.30
in general payments reported to CMS, 2019-2025
43 companies · $846 in 2025
The $846 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $486 · 2021: $794 · 2022: $1,121 · 2023: $1,358 · 2024: $805 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.27 | 2020-2025 | Vraylar, Qulipta, Viberzi |
| Novo Nordisk INC | $705.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $553.44 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $546.62 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Corium, LLC | $333.12 | 2022-2025 | Azstarys |
| Pfizer INC. | $316.02 | 2020-2025 | |
| Allergan, INC. | $290.11 | 2019-2020 | |
| Abbott Laboratories | $273.21 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $196.45 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $191.85 | 2021-2025 | Rexulti |
| Steris Corporation | $157.66 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.45 | 2022 | |
| Lilly USA, LLC | $141.48 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Getinge USA Sales, LLC | $123.32 | 2022 | |
| Supernus Pharmaceuticals, INC. | $111.55 | 2021-2025 | Qelbree |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.